In contrast, no differences were found when RCTs were stratified according to the specific SGLT2 inhibitor or the presence or absence of other specific inclusion criteria, such as DM, CKD, or the timing of HF (acute vs. chronic). The gene discussed is SLC5A2; the disease is chronic kidney disease.